A citation-based method for searching scientific literature

Stijn De Munter, Alexander Van Parys, Layla Bral, Joline Ingels, Glenn Goetgeluk, Sarah Bonte, Melissa Pille, Lore Billiet, Karin Weening, Annick Verhee, Jose Van der Heyden, Tom Taghon, Georges Leclercq, Tessa Kerre, Jan Tavernier, Bart Vandekerckhove. Int J Mol Sci 2020
Times Cited: 7







List of co-cited articles
72 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Nanobodies: natural single-domain antibodies.
Serge Muyldermans. Annu Rev Biochem 2013
893
71

Nanobody Based Dual Specific CARs.
Stijn De Munter, Joline Ingels, Glenn Goetgeluk, Sarah Bonte, Melissa Pille, Karin Weening, Tessa Kerre, Hinrich Abken, Bart Vandekerckhove. Int J Mol Sci 2018
55
71

Theranostics in immuno-oncology using nanobody derivatives.
Quentin Lecocq, Yannick De Vlaeminck, Heleen Hanssens, Matthias D'Huyvetter, Geert Raes, Cleo Goyvaerts, Marleen Keyaerts, Nick Devoogdt, Karine Breckpot. Theranostics 2019
38
57

Naturally occurring antibodies devoid of light chains.
C Hamers-Casterman, T Atarhouch, S Muyldermans, G Robinson, C Hamers, E B Songa, N Bendahman, R Hamers. Nature 1993
57

The Therapeutic Potential of Nanobodies.
Ivana Jovčevska, Serge Muyldermans. BioDrugs 2020
149
57

Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics.
Peter Bannas, Julia Hambach, Friedrich Koch-Nolte. Front Immunol 2017
182
57

Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice.
Yushu Joy Xie, Michael Dougan, Noor Jailkhani, Jessica Ingram, Tao Fang, Laura Kummer, Noor Momin, Novalia Pishesha, Steffen Rickelt, Richard O Hynes,[...]. Proc Natl Acad Sci U S A 2019
96
57

Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer.
Mahmoud Hassani, Fatemeh Hajari Taheri, Zahra Sharifzadeh, Arash Arashkia, Jamshid Hadjati, Wytske M van Weerden, Mohammad Hossein Modarressi, Mohsen Abolhassani. J Cell Biochem 2019
20
57

Development of VEGFR2-specific Nanobody Pseudomonas exotoxin A conjugated to provide efficient inhibition of tumor cell growth.
Mahdi Behdani, Sirous Zeinali, Morteza Karimipour, Hossein Khanahmad, Steve Schoonooghe, Azam Aslemarz, Negar Seyed, Reza Moazami-Godarzi, Farzad Baniahmad, Mahdi Habibi-Anbouhi,[...]. N Biotechnol 2013
49
42


Nanobody-derived nanobiotechnology tool kits for diverse biomedical and biotechnology applications.
Yongzhong Wang, Zhen Fan, Lei Shao, Xiaowei Kong, Xianjuan Hou, Dongrui Tian, Ying Sun, Yazhong Xiao, Li Yu. Int J Nanomedicine 2016
52
42

Nanobody-Based Delivery Systems for Diagnosis and Targeted Tumor Therapy.
Yaozhong Hu, Changxiao Liu, Serge Muyldermans. Front Immunol 2017
66
42

T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
Fatemeh Rahimi Jamnani, Fatemeh Rahbarizadeh, Mohammad Ali Shokrgozar, Fereidoun Mahboudi, Davoud Ahmadvand, Zahra Sharifzadeh, Ladan Parhamifar, S Moein Moghimi. Biochim Biophys Acta 2014
39
42

General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold.
Cécile Vincke, Remy Loris, Dirk Saerens, Sergio Martinez-Rodriguez, Serge Muyldermans, Katja Conrath. J Biol Chem 2009
256
42

A caspase 8-based suicide switch induces apoptosis in nanobody-directed chimeric receptor expressing T cells.
Sepideh Khaleghi, Fatemeh Rahbarizadeh, Davoud Ahmadvand, Mohammad J Rasaee, Philippe Pognonec. Int J Hematol 2012
25
42

T cell engineered with a novel nanobody-based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy.
Fatemeh Hajari Taheri, Mahmoud Hassani, Zahra Sharifzadeh, Mehdi Behdani, Arash Arashkia, Mohsen Abolhassani. IUBMB Life 2019
16
42

Improved Antitumor Efficacy of Chimeric Antigen Receptor T Cells that Secrete Single-Domain Antibody Fragments.
Yushu Joy Xie, Michael Dougan, Jessica R Ingram, Novalia Pishesha, Tao Fang, Noor Momin, Hidde L Ploegh. Cancer Immunol Res 2020
19
42




Nanobody-based cancer therapy of solid tumors.
Marta Kijanka, Bram Dorresteijn, Sabrina Oliveira, Paul M P van Bergen en Henegouwen. Nanomedicine (Lond) 2015
127
28

Nanobodies and their potential applications.
Gholamreza Hassanzadeh-Ghassabeh, Nick Devoogdt, Pieter De Pauw, Cécile Vincke, Serge Muyldermans. Nanomedicine (Lond) 2013
160
28

Targeting tumors with nanobodies for cancer imaging and therapy.
Sabrina Oliveira, Raimond Heukers, Jirawas Sornkom, Robbert J Kok, Paul M P van Bergen En Henegouwen. J Control Release 2013
126
28

Nanobody Technology for Mycotoxin Detection in the Field of Food Safety: Current Status and Prospects.
Ting He, Jiang Zhu, Yao Nie, Rui Hu, Ting Wang, Peiwu Li, Qi Zhang, Yunhuang Yang. Toxins (Basel) 2018
15
28

Recent advances in the selection and identification of antigen-specific nanobodies.
Wenshuai Liu, Haipeng Song, Quan Chen, Jianli Yu, Mo Xian, Rui Nian, Dongxiao Feng. Mol Immunol 2018
26
28


Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers.
Roghaye Arezumand, Abbas Alibakhshi, Javad Ranjbari, Ali Ramazani, Serge Muyldermans. Front Immunol 2017
31
28


The structural basis of nanobody unfolding reversibility and thermoresistance.
Patrick Kunz, Katinka Zinner, Norbert Mücke, Tanja Bartoschik, Serge Muyldermans, Jörg D Hoheisel. Sci Rep 2018
39
28

Nanobodies as Probes for Protein Dynamics in Vitro and in Cells.
Oleg Y Dmitriev, Svetlana Lutsenko, Serge Muyldermans. J Biol Chem 2016
58
28

Nanobodies and Cancer: Current Status and New Perspectives.
Alessandro Allegra, Vanessa Innao, Demetrio Gerace, Doriana Vaddinelli, Andrea Gaetano Allegra, Caterina Musolino. Cancer Invest 2018
11
28

Single-Domain Antibodies As Versatile Affinity Reagents for Analytical and Diagnostic Applications.
Gualberto Gonzalez-Sapienza, Martín A Rossotti, Sofía Tabares-da Rosa. Front Immunol 2017
67
28

Nanobodies as therapeutics: big opportunities for small antibodies.
Sophie Steeland, Roosmarijn E Vandenbroucke, Claude Libert. Drug Discov Today 2016
167
28

Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo.
David Maussang, Azra Mujić-Delić, Francis J Descamps, Catelijne Stortelers, Peter Vanlandschoot, Marijke Stigter-van Walsum, Henry F Vischer, Maarten van Roy, Maria Vosjan, Maria Gonzalez-Pajuelo,[...]. J Biol Chem 2013
98
28

A Nanobody Against Cytotoxic T-Lymphocyte Associated Antigen-4 Increases the Anti-Tumor Effects of Specific CD8+ T Cells.
Zhuoran Tang, Fengzhen Mo, Aiqun Liu, Siliang Duan, Xiaomei Yang, Liu Liang, Xiaoqiong Hou, Shihua Yin, Xiaobing Jiang, Natalia Vasylieva,[...]. J Biomed Nanotechnol 2019
7
28

Nanobody: outstanding features for diagnostic and therapeutic applications.
J-Pablo Salvador, Lluïsa Vilaplana, M-Pilar Marco. Anal Bioanal Chem 2019
55
28

A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks.
A S Greenberg, D Avila, M Hughes, A Hughes, E C McKinney, M F Flajnik. Nature 1995
444
28

In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.
Carlos A Ramos, Rayne Rouce, Catherine S Robertson, Amy Reyna, Neeharika Narala, Gayatri Vyas, Birju Mehta, Huimin Zhang, Olga Dakhova, George Carrum,[...]. Mol Ther 2018
90
28

Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents.
Zahra Sharifzadeh, Fatemeh Rahbarizadeh, Mohammad A Shokrgozar, Davoud Ahmadvand, Fereidoun Mahboudi, Fatemeh Rahimi Jamnani, S Moein Moghimi. Cancer Lett 2013
42
28


Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells.
Na An, Yun Nan Hou, Qiao Xia Zhang, Ting Li, Qiong Li Zhang, Cheng Fang, Huan Chen, Hon Cheung Lee, Yong Juan Zhao, Xin Du. Mol Pharm 2018
28
28

Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38+ tumors in mouse models in vivo.
William Fumey, Julia Koenigsdorf, Valentin Kunick, Stephan Menzel, Kerstin Schütze, Mandy Unger, Levin Schriewer, Friedrich Haag, Gerhard Adam, Anna Oberle,[...]. Sci Rep 2017
35
28

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.
Adrienne H Long, Waleed M Haso, Jack F Shern, Kelsey M Wanhainen, Meera Murgai, Maria Ingaramo, Jillian P Smith, Alec J Walker, M Eric Kohler, Vikas R Venkateshwara,[...]. Nat Med 2015
698
28

Comparison of llama VH sequences from conventional and heavy chain antibodies.
K B Vu, M A Ghahroudi, L Wyns, S Muyldermans. Mol Immunol 1997
210
28

Anti-MUC1 nanobody can redirect T-body cytotoxic effector function.
Seyed Hamid Aghaee Bakhtiari, Fatemeh Rahbarizadeh, Sadegh Hasannia, Davoud Ahmadvand, Farnoush Jafari Iri-Sofla, Mohammad Javad Rasaee. Hybridoma (Larchmt) 2009
29
28


Cancer regression in patients after transfer of genetically engineered lymphocytes.
Richard A Morgan, Mark E Dudley, John R Wunderlich, Marybeth S Hughes, James C Yang, Richard M Sherry, Richard E Royal, Suzanne L Topalian, Udai S Kammula, Nicholas P Restifo,[...]. Science 2006
28

A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia.
Gunilla Enblad, Hannah Karlsson, Gustav Gammelgård, Jessica Wenthe, Tanja Lövgren, Rose Marie Amini, Kristina I Wikstrom, Magnus Essand, Barbara Savoldo, Helene Hallböök,[...]. Clin Cancer Res 2018
88
28

A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform.
Susann Albert, Claudia Arndt, Anja Feldmann, Ralf Bergmann, Dominik Bachmann, Stefanie Koristka, Florian Ludwig, Pauline Ziller-Walter, Alexandra Kegler, Sebastian Gärtner,[...]. Oncoimmunology 2017
55
28



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.